Bevacizumab in first-line postoperative treatment of advanced ovarian cancer: from high-risk stratification to precision decision-making
Bevacizumab is an important component of first-line therapy for advanced epithelial ovarian cancer; however, the precise identification of patients who will benefit and how to optimize its use in the era of poly (ADP-ribose) polymerase inhibitors (PARPi) remains a core challenge in clinical practice. This review system...